Incidence of antibody–drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.

Antibody–drug conjugates (ADCs) have demonstrated significant efficacy in treating solid tumors. However, the occurrence of ADC drug-associated pneumonitis can limit the use of ADCs or have severe consequences, and we know comparatively little about this. PubMed, EMBASE, and the Cochrane library were exhaustively searched for articles and conference abstracts published before September 30, 2022. Two authors independently extracted data from the included studies. A random-effects model was used to conduct a meta-analysis of the relevant outcomes. Forest plots reflected the incidence rates from each study, and binomial methods were used to calculate the 95 % confidence interval. This meta-analysis included 7732 patients from 39 studies and evaluated the incidence of ADCs drug-associated pneumonitis which have received market approval for the treatment of solid tumors. The total incidence of solid tumors for all-grade pneumonitis was 5.86 % (95 % CI, 3.54–8.66 %) and for grade ≥3 was 0.68 % (95 % CI, 0.18–1.38 %). The incidence of all-grade pneumonitis was 5.08 % (95 % CI, 2.76–7.96 %) and for grade ≥3 was 0.57 % (95 % CI, 0.10–1.29 %) with ADC monotherapy. The incidence of all-grade and grade ≥3 pneumonitis in trastuzumab deruxtecan (T-DXd) was 13.58 % (95 % CI, 9.43–18.29 %) and 2.19 % (95 % CI, 0.94–3.81 %), respectively, the highest in ADC therapy. Total incidence of all-grade pneumonitis was 10.58 % (95 % CI, 4.34–18.81 %) and for grade ≥3 pneumonitis was 1.29 % (95 % CI, 0.22–2.92 %) with ADC combination therapy. The incidence of pneumonitis was higher with combination therapy than with monotherapy in both all-grade and grade ≥3 groups, but there was no statistical significance (P =.138 and P =.281, respectively). The incidence of ADC-associated pneumonitis in non-small cell lung cancer (NSCLC) was 22.18 % (95 % CI, 2.14–52.61 %), the highest among solid tumors. The 11 included studies reported 21 pneumonitis-related deaths. Our findings will assist clinicians in choosing the optimal therapeutic options for patients with solid tumors treated with ADCs. [Display omitted] • This is the first meta-analysis to assess the incidence of pneumonitis caused by approved antibody–drug conjugates (ADCs). • Patients with solid tumors had a higher incidence of all-grade ADC drug-associated pneumonitis, grade ≥3 was relatively rare. • The incidence of pneumonitis varies according to drug and tumor type. [ABSTRACT FROM AUTHOR]